Blogs

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

Reducing variability in gene expression: Bottlenecks and Solutions
Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.
23rd Jan, 2025
Read
Quantifying a biomarker in mice brain for treating mood and anxiety disorders
A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.
18th Oct, 2024
Read
Risk assessment strategy for nitrosamine drug substance-related impurities
The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.
2nd Sep, 2024
Read
Innovation at Syngene: Translatable models for improving cancer research
Syngene has developed orthotopic models validated against the standard of care and tumor models with 3D culture, which can help improve translatability and clinical relevance in cancer research.
12th Jun, 2024
Read
pDNA and mRNA manufacturing in the age of Precision Therapies: The role of CDMOs
Challenges in pDNA manufacturing and why CDMOs are best suited for supplying pDNA for Precision Therapies.
28th Nov, 2023
Read
Leveraging High Throughput Screening services to accelerate drug discovery and development
The many applications of HTS and how it has evolved beyond lead identification and candidate optimization today.
18th Aug, 2023
Read
Harnessing the power of induced proximity-based drugs and precision medicine for treating cancer
How Syngene is supporting clients in treating cancer using targeted protein degradation, protein stabilization approaches, and precision medicine therapies.
19th Jun, 2023
Read
Five questions that determine the success of your PROTAC programs
Challenges in developing PROTACs and critical questions that need to be addressed to move PROTAC molecules from Target to IND successfully.
18th Oct, 2022
Read
Solving problems with science: Gene to GMP-grade clinical supply in nine months
How Syngene’s proprietary data platform is safely and efficiently reducing the time taken to produce mAbs from gene to GMP-grade clinical supply by several months.
6th Sep, 2022
Read
Minimizing environmental footprint the Syngene way
How Syngene is driving behavioural change in responsible use of natural resources while researching new technology and opportunities to improve its sustainability performance continuously.
24th Jun, 2022
Read

Sign-up for our newsletter

© 2025. Syngene International Limited

Linkedin-in Youtube Facebook-f

Quick links

Business

Get in touch

Other links
Linkedin-in Youtube Facebook-f

© 2025. Syngene International Limited

To view or email, Please share your details view

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details